News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

Press Release

Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting

May 22, 2025

Read Now

Press Release

Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting

May 22, 2025

Read Now

Press Release

Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division

May 5, 2025

Read Now

Press Release

Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division

May 5, 2025

Read Now

Press Release

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders

April 28, 2025

Read Now

Press Release

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders

April 28, 2025

Read Now

Press Release

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

April 23, 2025

Read Now

Press Release

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

April 23, 2025

Read Now

News

CRISPRMED25 Virtual Event Roundup

April 8, 2025

CRISPR Medicine News

Read Now

Press Release

CRISPRMED25 Virtual Event Roundup

April 8, 2025

CRISPR Medicine News

Read Now

News

From Tools to Trials: Editing Therapy Companies Pivot to Development

March 20, 2025

Genetic Engineering & Biotechnology News

Read Now

Press Release

From Tools to Trials: Editing Therapy Companies Pivot to Development

March 20, 2025

Genetic Engineering & Biotechnology News

Read Now

News

Industry appetite for natural killer cells intensifies

February 15, 2023

Nature Biotechnology

Read Now

News

Economic Forecast 2023

January 6, 2023

San Francisco Business Times

Read Now

News

Building a biotech in a downturn: 3 lessons from VCs and startup CEOs

November 3, 2022

Biopharma Dive

Read Now

News

Deals In Depth: September 2022

October 18, 2022

In Vivo

Read Now

News

Scribe and Sanofi partner to develop cell therapies for cancer

September 28, 2022

Pharmaceutical Technology

Read Now

News

Follow the Money

September 28, 2022

Bio-IT World

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 29, 2022

Read Now

Press release

Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer

September 27, 2022

Read Now

Press release

Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires

July 26, 2022

Read Now

Press release

Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect

July 15, 2022

Read Now

Press release

Scribe Therapeutics Expands Collaboration With Biogen to Second Target

May 2, 2022

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference

April 1, 2022

Read Now

Publications and presentations

Presentation

Scribe Corporate Deck 2025 Q1

February 3, 2025

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now